GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: June 25, 2003, 14:20:41 ; Search time 33.3 Seconds
(without alignments)
444.169 Million cell updates/sec

Title: US-09-622-613B-21
Perfect score: 605
Sequence: 1 MQNWATFQQKHIINTPIICN.....ICVKCENQYPVHFAGIGRCP 111

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	605	100.0	111	20	AAY28876	Recombinant Met(-1
2	601	99.3	111	20	AAY28873	Recombinant Met(-1
3	600	99.2	110	20	AAY28874	Recombinant RaCOR1
4	596	98.5	110	20	AAY28872	Rana catesbeiana o
5	596	98.5	111	20	AAY28878	Recombinant Met(-1
6	591	97.7	110	20	AAY28877	Recombinant RaCOR1
7	582.5	96.3	111	20	AAY33321	Frog lectin protei
8	284.5	47.0	105	20	AAY28869	Recombinant Met(-1
9	282.5	46.7	105	20	AAY28867	Recombinant Met(-1
10	280.5	46.4	104	18	AAW06544	Antitumour protein
11	279.5	46.2	104	20	AAY28866	Recombinant RaPLR1
12	278.5	46.0	105	20	AAY39400	Recombinant frog O
13	277.5	45.9	104	20	AAY28865	Rana pipiens liver
14	277.5	45.9	105	20	AAY28871	Recombinant Met(-1
15	277.5	45.9	127	20	AAY28879	Rana pipiens Clone
16	275.5	45.5	105	18	AAW35123	R. pipiens recombi
17	275.5	45.5	355	18	AAW35125	R. pipiens recombi
18	275.5	45.5	358	18	AAW35130	R. pipiens recombi
19	273.5	45.2	104	18	AAW30301	Recombinant onc pr
20	273.5	45.2	104	22	AAB31666	Amino acid sequenc
21	273.5	45.2	104	22	AAB31667	Amino acid sequenc
22	273.5	45.2	112	18	AAW35118	R. pipiens recombi
23	273.5	45.2	251	18	AAW35134	R. pipiens recombi
24	273.5	45.2	254	18	AAW35135	R. pipiens recombi
25	273.5	45.2	355	18	AAW35129	R. pipiens recombi
26	273.5	45.2	355	18	AAW35133	R. pipiens recombi
27	273.5	45.2	366	18	AAW35132	R. pipiens recombi
28	273.5	45.2	379	18	AAW35126	R. pipiens recombi
29	272.5	45.0	104	18	AAW30302	Recombinant onc pr
30	272.5	45.0	104	20	AAY28870	Recombinant RaPLR1
31	270.5	44.7	104	12	AAR12344	Protein with activ
32	270.5	44.7	104	15	AAR47303	ONCONASE (pharmace
33	270.5	44.7	104	17	AAW00736	Protein derived fr
34	270.5	44.7	104	18	AAW06543	Antitumour protein
35	270.5	44.7	104	18	AAW14065	Onconase (RTM) pro
36	270.5	44.7	104	20	AAY33322	Frog onconase prot
37	270.5	44.7	104	20	AAW88233	Rana pipiens RNase
38	268.5	44.4	105	18	AAW35116	R. pipiens recombi
39	268.5	44.4	106	18	AAW35122	R. pipiens recombi
40	268.5	44.4	107	18	AAW35117	R. pipiens recombi
41	267.5	44.2	105	18	AAW35115	R. pipiens recombi
42	264.5	43.7	358	18	AAW35127	R. pipiens recombi
43	264.5	43.7	365	18	AAW35131	R. pipiens recombi
44	263.5	43.6	104	18	AAW18224	Antitumour generic
45	246.5	40.7	107	18	AAW35120	R. pipiens recombi

ALIGNMENTS

RESULT 1
AAY28876
ID AAY28876 standard; Protein; 111 AA.
XX
AC AAY28876;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant Met(-1) RaCOR1 Met22Leu Met57Leu-(His)6 protein.
XX
KW Met(-1) Rana catesbeiana ribonuclease Met22Leu Met57Leu-(His)6; RaCOR1;
KW recombinant; CD22; covalently bound; LL2 antibody; ligand binding moiety;
KW cancerous B cell; Kaposi's sarcoma; human chorionic gonadotrophin; hCG;
KW signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW cancer; bullfrog; RNase; autoimmune disease.
XX
OS Rana catesbeiana.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 1
FT /note= "(His)6 histidine tag attached to N-terminal Met"
FT Misc-difference 1
FT /note= "Met not found in wild type RaCOR1"
FT Misc-difference 23
FT /note= "Wild type Met replaced with Leu"
FT Misc-difference 58
FT /note= "Wild type Met replaced with Leu"
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX

PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Newton DL, Rybak SM;
XX
DR WPI; 1999-610847/52.
DR N-PSDB; AAZ08133.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases -
XX
PS Claim 22; Page 66; 71pp; English.
XX
CC The present sequence is a recombinant Rana catesbeiana oocyte
CC ribonuclease (RaCOR1) protein with Met at position 1 attached to a
CC (His)6 tag, Met23Leu and Met58Leu. Carboxy terminal end of recombinant
CC RaCOR1 has a covalently bound ligand binding moiety, which can be a LL2
CC antibody directed against CD22 on cancerous B cells or human chorionic
CC gonadotrophin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC ribonucleases can be expressed in bacteria without an N-terminal
CC methionine due to the presence of a signal peptide that is cleaved by
CC bacteria. The soluble expression of ribonuclease allows the proteins to
CC be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC proteins. They can be used for treatment of cancer and autoimmune
CC diseases.
XX
SQ Sequence 111 AA;

Query Match 100.0%; Score 605; DB 20; Length 111;
Best Local Similarity 100.0%; Pred. No. 7e-61;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MQNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNV 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MQNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNV 60

Qy 61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
|||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111

RESULT 2
AAY28873
ID AAY28873 standard; Protein; 111 AA.
XX
AC AAY28873;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant Met(-1) RaCOR1.
XX
KW Recombinant Met(-1) Rana catesbeiana oocyte ribonuclease; RaCOR1; CD22;
KW covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW recombinant ribonuclease; cytotoxic fusion protein; cancer; bullfrog;
KW RNase; autoimmune disease.
XX
OS Rana catesbeiana.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 1
FT /note= "Met not found in wild type RaCOR1"
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX
PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Newton DL, Rybak SM;
XX
DR WPI; 1999-610847/52.
DR N-PSDB; AAZ08131.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases -
XX
PS Claim 22; Page 63; 71pp; English.
XX
CC The present sequence is a recombinant Rana catesbeiana oocyte
CC ribonuclease (RaCOR1) protein with Met at position 1. Carboxy terminal
CC end of recombinant RaCOR1 has a covalently bound ligand binding moiety,
CC which can be a LL2 antibody directed against CD22 on cancerous B cells or
CC human chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma
CC cells. Recombinant ribonucleases can be expressed in bacteria without an
CC N-terminal methionine due to the presence of a signal peptide that is
CC cleaved by bacteria. The soluble expression of ribonuclease allows the
CC proteins to be fused in-frame with ligand binding moieties to form
CC cytotoxic fusion proteins. They can be used for treatment of cancer and
CC autoimmune diseases.
XX
SQ Sequence 111 AA;

Query Match 99.3%; Score 601; DB 20; Length 111;
Best Local Similarity 98.2%; Pred. No. 2e-60;
Matches 109; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MQNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNV 60
|||||||||||||||||||||:|||||||||||||||||||||||||||||||:||
Db 1 MQNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60

Qy 61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
|||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111

RESULT 3
AAY28874
ID AAY28874 standard; Protein; 110 AA.
XX
AC AAY28874;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant RaCOR1 Met22Leu Met57Leu amino acid sequence.
XX
KW Recombinant Rana catesbeiana oocyte ribonuclease; covalently bound;
KW RaCOR1 Met22Leu Met57Leu; LL2 antibody; ligand binding moiety; CD22;
KW cancerous B cell; Kaposi's sarcoma; human chorionic gonadotrophin; hCG;
KW signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW cancer; bullfrog; RNase; autoimmune disease.
XX
OS Rana catesbeiana.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 22
FT /note= "Wild type Met replaced with Leu"
FT Misc-difference 57
FT /note= "Wild type Met replaced with Leu"
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX
PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.

```
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08132.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 22; Page 64; 71pp; English.
XX
CC   The present sequence is a recombinant Rana catesbeiana oocyte
CC   ribonuclease (RaCOR1) protein with Met22Leu Met57Leu. Carboxy terminal
CC   end of recombinant RaCOR1 has a covalently bound ligand binding moiety,
CC   which can be a LL2 antibody directed against CD22 on cancerous B cells
CC   or human chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma
CC   cells. Recombinant ribonucleases can be expressed in bacteria without an
CC   N-terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence   110 AA;

  Query Match           99.2%;  Score 600;  DB 20;  Length 110;
  Best Local Similarity  100.0%;  Pred. No. 2.5e-60;
  Matches  110;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNVL 61
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 QNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNVL 60

Qy         62 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 110


RESULT 4
AAY28872
ID   AAY28872 standard; Protein; 110 AA.
XX
AC   AAY28872;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Rana catesbeiana oocyte ribonuclease (RaCOR1) amino acid sequence.
XX
KW   Rana catesbeiana oocyte ribonuclease; RaCOR1; covalently bound; CD22;
KW   LL2 antibody; ligand binding moiety; cancerous B cell; Kaposi's Sarcoma;
KW   human chorionic gonadotrophin; hCG; recombinant ribonuclease; bullfrog;
KW   signal peptide; cytotoxic fusion protein; cancer; autoimmune disease;
KW   RNase.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08130.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 22; Page 62; 71pp; English.
XX
CC   The present sequence is a Rana catesbeiana oocyte ribonuclease (RaCOR1)
CC   protein encoded by a cDNA modified for expression in E. coli. Carboxy
CC   terminal end of RaCOR1 has a covalently bound ligand binding moiety,
CC   which can be a LL2 antibody directed against CD22 on cancerous B cells
CC   or human chorionic gonadotrophin (hCG) effective against Kaposi's
CC   Sarcoma cells. Recombinant ribonucleases can be expressed in bacteria
CC   without an N-terminal methionine due to the presence of a signal peptide
CC   that is cleaved by bacteria. The soluble expression of ribonuclease
CC   allows the proteins to be fused in-frame with ligand binding moieties to
CC   form cytotoxic fusion proteins. They can be used for treatment of cancer
CC   and autoimmune diseases.
XX
SQ   Sequence   110 AA;

  Query Match           98.5%;  Score 596;  DB 20;  Length 110;
  Best Local Similarity  98.2%;  Pred. No. 7.2e-60;
  Matches  108;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNVL 61
              |||||||||||||||||||:|||||||||||||||||||||||||||||||:|||||||
Db          1 QNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVL 60

Qy         62 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 STTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 110


RESULT 5
AAY28878
ID   AAY28878 standard; Protein; 111 AA.
XX
AC   AAY28878;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaCOR1 Gln1Ser amino acid sequence.
XX
KW   Recombinant Met(-1) Rana catesbeiana oocyte ribonuclease Gln1Ser; RaCOR1;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; bullfrog;
KW   CD22; RNase; autoimmune disease.
XX
OS   Rana catesbeiana.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaCOR1"
FT   Misc-difference 2
FT                   /note= "Wild type Gln replaced with Ser"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08135.
XX
```

PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases -
XX
PS Claim 22; Page 68; 71pp; English.
XX
CC The present sequence is a recombinant Rana catesbeiana ribonuclease
CC (RaCOR1) protein with Met at position 1 and Gln2Ser. Carboxy terminal end
CC of recombinant RaCOR1 has a covalently bound ligand binding moiety, which
CC can be a LL2 antibody directed against CD22 on cancerous B cells or human
CC chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma cells.
CC Recombinant ribonucleases can be expressed in bacteria without an N-
CC terminal methionine due to the presence of a signal peptide that is
CC cleaved by bacteria. The soluble expression of ribonuclease allows the
CC proteins to be fused in-frame with ligand binding moieties to form
CC cytotoxic fusion proteins. They can be used for treatment of cancer and
CC autoimmune diseases.
XX
SQ Sequence 111 AA;

Query Match 98.5%; Score 596; DB 20; Length 111;
Best Local Similarity 97.3%; Pred. No. 7.3e-60;
Matches 108; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MQNWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNV 60
Db 1 MSNWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60

Qy 61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
Db 61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111

RESULT 6
AAY28877
ID AAY28877 standard; Protein; 110 AA.
XX
AC AAY28877;
XX
DT 25-JAN-2000 (first entry)
XX
DE Recombinant RaCOR1 Gln1Ser amino acid sequence.
XX
KW Recombinant Rana catesbeiana oocyte ribonuclease; RaCOR1 Gln1Ser; CD22;
KW covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW bullfrog; Kaposi's sarcoma; human chorionic gonadotrophin; hCG; RNase;
KW signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW cancer; autoimmune disease.
XX
OS Rana catesbeiana.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 1
FT /note= "Wild type Gln replaced with Ser"
XX
PN WO9950398-A2.
XX
PD 07-OCT-1999.
XX
PF 26-MAR-1999; 99WO-US06641.
XX
PR 27-MAR-1998; 98US-0079751.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Newton DL, Rybak SM;
XX
DR WPI; 1999-610847/52.
DR N-PSDB; AAZ08134.
XX
PT New recombinant ribonucleases, used for killing target cells, e.g. for
PT treating cancers, viral infections or autoimmune diseases -
XX
PS Claim 22; Page 67; 71pp; English.
XX
CC The present sequence is a recombinant Rana catesbeiana oocyte
CC ribonuclease (RaCOR1) protein with Gln1Ser. Carboxy terminal end of
CC recombinant RaCOR1 has a covalently bound ligand binding moiety, which
CC can be a LL2 antibody directed against CD22 on cancerous B cells or
CC human chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma
CC cells. Recombinant ribonucleases can be expressed in bacteria without an
CC N-terminal methionine due to the presence of a signal peptide that is
CC cleaved by bacteria. The soluble expression of ribonuclease allows the
CC proteins to be fused in-frame with ligand binding moieties to form
CC cytotoxic fusion proteins. They can be used for treatment of cancer and
CC autoimmune diseases.
XX
SQ Sequence 110 AA;

Query Match 97.7%; Score 591; DB 20; Length 110;
Best Local Similarity 98.2%; Pred. No. 2.7e-59;
Matches 107; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3 NWATFQQKHIINTPIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNVLS 62
Db 2 NWATFQQKHIINTPIICNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNVLS 61

Qy 63 TTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
Db 62 TTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 110

RESULT 7
AAY33321
ID AAY33321 standard; Protein; 111 AA.
XX
AC AAY33321;
XX
DT 29-NOV-1999 (first entry)
XX
DE Frog lectin protein fragment.
XX
KW Cytotoxic; RNase; ribonuclease; pancreatic; antibody; light chain;
KW heavy chain; cell surface marker; treatment; tumor; viral infection;
KW parasite infection; immune dysfunctional cell; autoimmune disease;
KW contraceptive; cell separation; transplantation; bone marrow ablation;
KW leukemia cell; T-cell; graft-versus-host disease; bullfrog; lectin.
XX
OS Rana catesbeiana.
XX
PN US5955073-A.
XX
PD 21-SEP-1999.
XX
PF 09-JUL-1997; 97US-0891848.
XX
PR 22-SEP-1993; 93US-0125462.
PR 22-OCT-1991; 91US-0779195.
PR 20-APR-1990; 90US-0510696.
PR 04-FEB-1993; 93US-0014082.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Rybak SM, Newton DL, Nicholls PJ, Youle RJ;
XX
DR WPI; 1999-560488/47.
XX
PT Recombinantly fused pancreatic RNase-targeting proteins useful for
PT treating tumors, infections, immune or autoimmune disorders and as a
PT contraceptive -
XX
PS Example 3; Fig 19; 47pp; English.
XX
CC This invention describes a novel nucleic acid construct comprising
CC sequences encoding functional pancreatic RNase and a second protein
CC (preferably the light and heavy chains of an antibody) which binds a

```
CC   specific cell surface marker on a target cell and functions as a
CC   cytotoxic agent. The products can be used for selectively killing cells
CC   expressing a specific surface marker. They can be used for treating
CC   tumors or infected cells (e.g. cells infected by viruses (especially
CC   latent or chronic virus infections, such as human immunodeficiency virus
CC   (HIV)-1, Epstein-Barr virus, herpes viruses (herpes simplex types I and
CC   II), hepatitis viruses (B, non-A-non-B, and delta), herpes zoster,
CC   cytomegalovirus)) and cells infected with parasites (such as the malaria
CC   parasite)). They can also be used for treating immune dysfunctional cells
CC   in immune and autoimmune diseases. Additionally, they may be used as
CC   contraceptives. Finally they can also be used for cell separation in
CC   vitro by selectively killing unwanted types of cells (e.g. in bone
CC   marrow) prior to transplantation into a patient undergoing marrow
CC   ablation by radiation or for killing leukemia cells or T-cells that would
CC   cause graft-versus-host disease. This sequence represents a bullfrog
CC   (Rana catesbeiana) lectin used to describe the method of the invention.
XX
SQ   Sequence   111 AA;

  Query Match             96.3%;  Score 582.5;  DB 20;  Length 111;
  Best Local Similarity   96.4%;  Pred. No. 2.5e-58;
  Matches  107;  Conservative    3;  Mismatches    0;  Indels    1;  Gaps    1;

Qy          2 QNWATFQQKHIINTPII-CNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINLNV 60
              :|||||||||||||||| |||||:|||||||||||||||||||||||||||||||||:|| |
Db          1 ENWATFQQKHIINTPIINCNTIMDNNIYIVGGQCKRVNTFIISSATTVKAICTGVINMNV 60

Qy         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111
              |||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRCP 111


RESULT 8
AAY28869
ID   AAY28869 standard; Protein; 105 AA.
XX
AC   AAY28869;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaPLR1 Met23Leu-(His)6 protein.
XX
KW   Recombinant Met(-1) Rana pipiens ribonuclease Met23Leu-(His)6; RaPLR1;
KW   CD22; covalently bound; LL2 antibody; ligand binding moiety; RNase;
KW   cancerous B cell; Kaposi's sarcoma; human chorionic gonadotrophin; hCG;
KW   signal peptide; recombinant ribonuclease; cytotoxic fusion protein;
KW   cancer; frog; autoimmune disease.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "(His)6 histidine tag attached to N-terminal Met"
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaPLR1"
FT   Misc-difference 24
FT                   /note= "Wild type Met replaced with Leu"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08127.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 4; Page 59; 71pp; English.
XX
CC   The present sequence is a recombinant Rana pipiens ribonuclease protein
CC   (RaPLR1) with Met at position 1 attached to (His)6 tag and Met24Leu.
CC   Carboxy terminal end of recombinant RaPLR1 has a covalently bound ligand
CC   binding moiety, which can be a LL2 antibody directed against CD22 on
CC   cancerous B cells or human chorionic gonadotrophin (hCG) effective
CC   against Kaposi's sarcoma cells. Recombinant ribonucleases can be
CC   expressed in bacteria without an N-terminal methionine due to the
CC   presence of a signal peptide that is cleaved by bacteria. The soluble
CC   expression of ribonuclease allows the proteins to be fused in-frame with
CC   ligand binding moieties to form cytotoxic fusion proteins. They can be
CC   used for treatment of cancer and autoimmune diseases.
XX
SQ   Sequence   105 AA;

  Query Match             47.0%;  Score 284.5;  DB 20;  Length 105;
  Best Local Similarity   50.0%;  Pred. No. 1.5e-24;
  Matches   56;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MQNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NL 58
              ||:| |||:||: ||  : || ||  |::     ||  |||| |    ||||| |:| :
Db          1 MQDWLTFQKKHLTNTRDVDCNNILSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 105


RESULT 9
AAY28867
ID   AAY28867 standard; Protein; 105 AA.
XX
AC   AAY28867;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaPLR1.
XX
KW   Recombinant Met(-1) Rana pipiens ribonuclease; RaPLR1; CD22; RNase;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW   autoimmune disease.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaPLR1"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08126.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
```

```
XX
PS   Claim 34; Page 57; 71pp; English.
XX
CC   The present sequence is a recombinant Rana pipiens ribonuclease (RaPLR1)
CC   protein with Met at position 1. Carboxy terminal end of recombinant
CC   RaPLR1 has a covalently bound ligand binding moiety, which can be a LL2
CC   antibody directed against CD22 on cancerous B cells or human chorionic
CC   gonadotrophin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC   ribonucleases can be expressed in bacteria without an N-terminal
CC   methionine due to the presence of a signal peptide that is cleaved by
CC   bacteria. The soluble expression of ribonuclease allows the proteins to
CC   be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC   proteins. They can be used for treatment of cancer and autoimmune
CC   diseases.
XX
SQ   Sequence   105 AA;

  Query Match             46.7%;  Score 282.5;  DB 20;  Length 105;
  Best Local Similarity   49.1%;  Pred. No. 2.5e-24;
  Matches   55;  Conservative   16;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MQNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NL 58
              ||:| |||:||: ||  : || |:  |::     ||  |||| |    ||||| |:| :
Db          1 MQDWLTFQKKHLTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 105


RESULT 10
AAW06544
ID   AAW06544 standard; protein; 104 AA.
XX
AC   AAW06544;
XX
DT   22-AUG-1997  (first entry)
XX
DE   Antitumour protein from Rana pipiens oocytes.
XX
KW   Tumour; chemotherapy; radiotherapy; frog.
XX
OS   Rana pipiens.
XX
PN   WO9639428-A1.
XX
PD   12-DEC-1996.
XX
PF   03-JUN-1996;   96WO-US08304.
XX
PR   06-JUN-1995;   95US-0467955.
XX
PA   (ALFA-) ALFACELL CORP.
XX
PI   Ardelt WJ;
XX
DR   WPI; 1997-043063/04.
XX
PT   Antitumour proteins from Rana pipiens oocyte(s) - have fewer
PT   disadvantages than chemotherapy, surgery and radiotherapy
XX
PS   Claim 8; Page 28; 45pp; English.
XX
CC   The present sequence is a specifically claimed example of an
CC   antitumour protein from the generic protein in AAW18224, with the
CC   molecular weight 12000. This is one of two preferred proteins (the
CC   other in AAW06543) that have been isolated from Rana pipiens oocytes.
CC   Both proteins have a blocked amino terminal group and are essentially
CC   free of carbohydrates. The proteins are used to treat tumours. Use of
CC   the peptides has fewer disadvantages than chemotherapy, radiotherapy
CC   and surgery in the treatment of tumours.
XX
SQ   Sequence   104 AA;

  Query Match             46.4%;  Score 280.5;  DB 18;  Length 104;
  Best Local Similarity   48.6%;  Pred. No. 4.2e-24;
  Matches   54;  Conservative   17;  Mismatches   31;  Indels    9;  Gaps    4;

Qy          2 QNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NLN 59
              ::| |||:||: ||  : || |:  |::     ||  |||| |    ||||| |:| : |
Db          1 EDWLTFQKKHVTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASKN 56

Qy         60 VLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              ||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:|||
Db         57 VLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGRC 104


RESULT 11
AAY28866
ID   AAY28866 standard; Protein; 104 AA.
XX
AC   AAY28866;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant RaPLR1 Met23Leu amino acid sequence.
XX
KW   Recombinant Rana pipiens ribonuclease; RaPLR1 Met23Leu; covalently bound;
KW   LL2 antibody; ligand binding moiety; CD22; cancerous B cell; RNase;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW   autoimmune disease.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 23
FT                   /note= "Wild type Met replaced with Leu"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08125.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases  -
XX
PS   Claim 34; Page 56; 71pp; English.
XX
CC   The present sequence is a recombinant Rana pipiens ribonuclease (RaPLR1)
CC   protein with Met23Leu. Carboxy terminal end of recombinant RaPLR1 has a
CC   covalently bound ligand binding moiety, which can be a LL2 antibody
CC   directed against CD22 on cancerous B cells or human chorionic
CC   gonadotrophin (hCG) effective against Kaposi's sarcoma cells. Recombinant
CC   ribonucleases can be expressed in bacteria without an N-terminal
CC   methionine due to the presence of a signal peptide that is cleaved by
CC   bacteria. The soluble expression of ribonuclease allows the proteins to
CC   be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC   proteins. They can be used for treatment of cancer and autoimmune
CC   diseases.
XX
SQ   Sequence   104 AA;

  Query Match             46.2%;  Score 279.5;  DB 20;  Length 104;
  Best Local Similarity   49.5%;  Pred. No. 5.5e-24;
```

```
  Matches   55;  Conservative   15;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          2 QNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NLN 59
              |:| |||:||: ||  : || ||  |::     ||  |||| |    ||||| |:| : |
Db          1 QDWLTFQKKHLTNTRDVDCNNILSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASKN 56

Qy         60 VLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              ||:|: |.|:|  |   ::| ||| ||  :  ||  || |||| |||| |:| |
Db         57 VLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 104


RESULT 12
AAY39400
ID   AAY39400 standard; Protein; 105 AA.
XX
AC   AAY39400;
XX
DT   01-DEC-1999  (first entry)
XX
DE   Recombinant frog Onconase.
XX
KW   Ribonuclease; protein synthesis; inhibition; cancer; cytotoxic.
XX
OS   Rana pipiens.
XX
PN   WO9946389-A1.
XX
PD   16-SEP-1999.
XX
PF   11-MAR-1999;   99WO-US04252.
XX
PR   11-MAR-1998;   98US-0077557.
XX
PA   (IMMU-) IMMUNOMEDICS INC.
XX
PI   Goldenberg DM,  Hansen H,  Leung S;
XX
DR   WPI; 1999-551416/46.
DR   N-PSDB; AAZ19767.
XX
PT   A new recombinant Onconase used to treat, e.g. colon cancer -
XX
PS   Example 1; Fig 1; 42pp; English.
XX
CC   This sequence represents recombinant frog Onconase. Onconase has
CC   ribonuclease and anti-tumour activity. The cDNA was produced via PCR
CC   (using primers AAZ19768-Z19769) of two synthetic DNAs whose sequences
CC   encoded most of the N-terminal or the C-terminal amino acids of mature
CC   Onconase. The two PCR products generated encoded either the N-terminal
CC   54 amino acids (minus the initial methionine) or the C-terminal 51 amino
CC   acids, and were ligated in frame at an NruI site. The cDNA was then
CC   subcloned into a vector e.g., pBluescript, where the ATG initiation
CC   codon was ligated to the cDNA. After expression in E. coli, the
CC   recombinant protein was purified. The initial N-formyl methionine was
CC   cleaved off and the now N-terminal glutamate residue cyclised to form an
CC   N-terminal pyroglutamate. The pyroglutamate residue forms part of the
CC   phosphate binding pocket of Onconaseand is essential for both
CC   ribonuclease and anti-tumour activity. Onconase is a 12 kD ribonuclease
CC   which causes cell death as a result of potent inhibition of protein
CC   synthesis by a mechanism involving inactivation of cellular RNA. It is
CC   not inhibited by mammalian placental ribonuclease inhibitor, which may
CC   explain its enhanced cytotoxicity relative to mammalian enzymes. It has
CC   anti-tumour activity against a variety of solid tumours e.g, colon or
CC   pancreatic cancers, and can be used alone or in combination with other
CC   anti-cancer agents such as tamoxifen. When used as an anti-tumour agent,
CC   Onconase can be conjugated to a marker which targets it to a specific
CC   cell type.
XX
SQ   Sequence   105 AA;

  Query Match           46.0%;  Score 278.5;  DB 20;  Length 105;
  Best Local Similarity 49.1%;  Pred. No. 7.2e-24;
  Matches   55;  Conservative   16;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          1 MQNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NLN 58
              ||:| |||:||| ||  : |: |:  |::     ||  |||| |    ||||| |:| :
Db          1 MQDWLTFQKKHITNTKDVDCDNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC 105


RESULT 13
AAY28865
ID   AAY28865 standard; Protein; 104 AA.
XX
AC   AAY28865;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Rana pipiens liver ribonuclease (RaPLR1).
XX
KW   Rana pipiens liver ribonuclease; RaPLR1; covalently bound; LL2 antibody;
KW   ligand binding moiety; CD22; cancerous B cell; Kaposi's Sarcoma; frog;
KW   human chorionic gonadotrophin; hCG; recombinant ribonuclease; RNase;
KW   signal peptide; cytotoxic fusion protein; cancer; autoimmune disease.
XX
OS   Rana pipiens.
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08124.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases -
XX
PS   Claim 1; Page 55; 71pp; English.
XX
CC   The present sequence is Rana pipiens liver ribonuclease (RaPLR1)
CC   protein. Carboxy terminal end of RaPLR1 has a covalently bound
CC   ligand binding moiety, which can be a LL2 antibody directed against
CC   CD22 on cancerous B cells or human chorionic gonadotrophin (hCG)
CC   effective against Kaposi's Sarcoma cells. Recombinant ribonucleases can
CC   be expressed in bacteria without an N-terminal methionine due to the
CC   presence of a signal peptide that is cleaved by bacteria. The soluble
CC   expression of ribonuclease allows the proteins to be fused in-frame with
CC   ligand binding moieties to form cytotoxic fusion proteins. They can be
CC   used for treatment of cancer and autoimmune diseases.
XX
SQ   Sequence   104 AA;

  Query Match           45.9%;  Score 277.5;  DB 20;  Length 104;
  Best Local Similarity 48.6%;  Pred. No. 9.3e-24;
  Matches   54;  Conservative   16;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          2 QNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NLN 59
              |:| |||:||: ||  : || |:  |::     ||  |||| |    ||||| |:| : |
Db          1 QDWLTFQKKHLTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASKN 56

Qy         60 VLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              ||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 VLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 104
```

```
RESULT 14
AAY28871
ID   AAY28871 standard; Protein; 105 AA.
XX
AC   AAY28871;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Recombinant Met(-1) RaPLR1 Gln1Ser amino acid sequence.
XX
KW   Recombinant Met(-1) Rana pipiens ribonuclease Gln1Ser; RaPLR1; CD22;
KW   covalently bound; LL2 antibody; ligand binding moiety; cancerous B cell;
KW   Kaposi's sarcoma; human chorionic gonadotrophin; hCG; signal peptide;
KW   recombinant ribonuclease; cytotoxic fusion protein; cancer; frog;
KW   autoimmune disease; RNase.
XX
OS   Rana pipiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Met not found in wild type RaPLR1"
FT   Misc-difference 2
FT                   /note= "Wild type Gln replaced with Ser"
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08129.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases  -
XX
PS   Claim 34; Page 61; 71pp; English.
XX
CC   The present sequence is a recombinant Rana pipiens ribonuclease (RaPLR1)
CC   protein with Met at position 1 and Gln2Ser. Carboxy terminal end of
CC   recombinant RaPLR1 has a covalently bound ligand binding moiety, which
CC   can be a LL2 antibody directed against CD22 on cancerous B cells or human
CC   chorionic gonadotrophin (hCG) effective against Kaposi's sarcoma cells.
CC   Recombinant ribonucleases can be expressed in bacteria without an N-
CC   terminal methionine due to the presence of a signal peptide that is
CC   cleaved by bacteria. The soluble expression of ribonuclease allows the
CC   proteins to be fused in-frame with ligand binding moieties to form
CC   cytotoxic fusion proteins. They can be used for treatment of cancer and
CC   autoimmune diseases.
XX
SQ   Sequence   105 AA;

  Query Match           45.9%;  Score 277.5;  DB 20;  Length 105;
  Best Local Similarity  48.2%;  Pred. No. 9.4e-24;
  Matches   54;  Conservative   16;  Mismatches   33;  Indels    9;  Gaps    4;

Qy          1 MQNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NL 58
              | :| |||:||: ||  : || |:  |::     ||  |||| |    ||||| |:| :
Db          1 MSDWLTFQKKHLTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASK 56

Qy         59 NVLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              |||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         57 NVLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 105


RESULT 15
```

```
AAY28879
ID   AAY28879 standard; Protein; 127 AA.
XX
AC   AAY28879;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Rana pipiens Clone 5a1b ribonuclease.
XX
KW   Rana pipiens ribonuclease Clone 5a1b; RaPLR1; covalently bound; RNase;
KW   LL2 antibody; ligand binding moiety; CD22; cancerous B cell; onconase;
KW   Kaposi's Sarcoma; human chorionic gonadotrophin; hCG; cancer;
KW   recombinant ribonuclease; frog; signal peptide; cytotoxic fusion protein;
KW   autoimmune disease.
XX
OS   Rana pipiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..23
FT                   /label= Signal_peptide
FT                   /note= "Putative"
FT   Protein         24..127
FT                   /label= Rana_pipiens_Clone_5a1b_ribonuclease
XX
PN   WO9950398-A2.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US06641.
XX
PR   27-MAR-1998;   98US-0079751.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Newton DL,  Rybak SM;
XX
DR   WPI; 1999-610847/52.
DR   N-PSDB; AAZ08136.
XX
PT   New recombinant ribonucleases, used for killing target cells, e.g. for
PT   treating cancers, viral infections or autoimmune diseases  -
XX
PS   Disclosure; Page 69; 71pp; English.
XX
CC   The present sequence is a Rana pipiens Clone 5a1b ribonuclease (RaPLR1).
CC   It is encoded by Clone 5a1b cDNA obtained from Rana pipiens liver mRNA
CC   library. It exhibits differences with Onconase (RTM) at amino acid
CC   residues 11, 20, 85 and 103. Carboxy terminal end of RaPLR1 has a
CC   covalently bound ligand binding moiety, which can be a LL2 antibody
CC   directed against CD22 on cancerous B cells or human chorionic
CC   gonadotrophin (hCG) effective against Kaposi's Sarcoma cells. Recombinant
CC   ribonucleases can be expressed in bacteria without an N-terminal
CC   methionine due to the presence of a signal peptide that is cleaved by
CC   bacteria. The soluble expression of ribonuclease allows the proteins to
CC   be fused in-frame with ligand binding moieties to form cytotoxic fusion
CC   proteins. They can be used for treatment of cancer and autoimmune
CC   diseases.
XX
SQ   Sequence   127 AA;

  Query Match           45.9%;  Score 277.5;  DB 20;  Length 127;
  Best Local Similarity  48.6%;  Pred. No. 1.2e-23;
  Matches   54;  Conservative   16;  Mismatches   32;  Indels    9;  Gaps    4;

Qy          2 QNWATFQQKHIINT-PIICNTILDNNIYIVGGQCKRVNTFIISSATTVKAICTGVI-NLN 59
              |:| |||:||: ||  : || |:  |::     ||  |||| |    ||||| |:| : |
Db         24 QDWLTFQKKHLTNTRDVDCNNIMSTNLF----HCKDKNTFIYSRPEPVKAICKGIIASKN 79

Qy         60 VLSTTRFQLNTCTRTSITPRPCPYSSRTETNYICVKCENQYPVHFAGIGRC 110
              ||:|: | |: |   ::| ||| |  :  ||  || |||| |||| |:| |
Db         80 VLTTSEFYLSDC---NVTSRPCKYKLKKSTNTFCVTCENQAPVHFVGVGHC 127
```

Search completed: June 25, 2003, 14:48:41
Job time : 34.3 secs